The impact of smoking on bronchiectasis and its comorbidities.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- de la Rosa-Carrillo, David
- de Granda-Orive, Jose Ignacio
- Diab Caceres, Layla
- Gutierrez Pereyra, Fernando
- Raboso Moreno, Beatriz
- Suarez-Cuartin, Guillermo
Grupos
Abstract
INTRODUCTION: Bronchiectasis, characterized by irreversible bronchial dilatation, is a growing global health concern with significant morbidity. This review delves into the intricate relationship between smoking and bronchiectasis, examining its epidemiology, pathophysiology, clinical manifestations, and therapeutic approaches. Our comprehensive literature search on PubMed utilized MESH terms including 'smoking,' 'smoking cessation,' 'bronchiectasis,' and 'comorbidities' to gather relevant studies. AREAS COVERED: This review emphasizes the role of smoking in bronchiectasis development and exacerbation by compromising airways and immune function. Interconnected comorbidities, including chronic obstructive pulmonary disease, asthma, and gastroesophageal reflux disease, create a detrimental cycle affecting patient outcomes. Despite limited studies on smoking cessation in bronchiectasis, the review stresses its importance. Advocating for tailored cessation programs, interventions like drainage, bronchodilators, and targeted antibiotics are crucial to disrupting the inflammatory-infection-widening cycle. EXPERT OPINION: The importance of smoking cessation in bronchiectasis management is paramount due to its extensive negative impact on related conditions. Proactive cessation programs utilizing technology and targeted education for high-risk groups aim to reduce smoking's impact on disease progression and related comorbidities. In conclusion, a personalized approach centered on smoking cessation is deemed vital for bronchiectasis, aiming to improve outcomes and enhance patients' quality of life in the face of this complex respiratory condition.
Datos de la publicación
- ISSN/ISSNe:
- 1747-6348, 1747-6356
- Tipo:
- Article
- Páginas:
- 255-268
- PubMed:
- 38888096
- Factor de Impacto:
- 0,939 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Expert review of respiratory medicine TAYLOR & FRANCIS LTD
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- Bronchiectasis; smoking; smoking cessation; bronchial inflammation; comorbidities; COPD
Proyectos y Estudios Clínicos
INTENSIFICACION DR. MIGUEL MARTINEZ GARCIA
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
INT11/037 . 2012
ASOCIACION ENTRE TRASTORNOS RESPIRATORIOS DEL SUEÑO Y TASA DE CRECIMIENTO DEL MELANOMA CUTANEO
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PI12/01363 . INSTITUTO DE SALUD CARLOS III . 2013
EFECTO DEL TRATAMIENTO CON CPAP SOBRE LAS CIFRAS TENSIONALES EN PACIENTES CON HIPERTENSION ARTERIAL REFRACTARIA. ESTUDIO MULTICENTRICO Y ALEATORIZADO. ESTUDIO HIPARCO
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PI09/01647 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010
INTENSIFICACION DR. MIGUEL ANGEL MARTINEZ GARCIA
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
INT14/00003 . INSTITUTO DE SALUD CARLOS III . 2015
ASOCIACIÓN ENTRE LOS TRASTORNOS RESPIRATORIOS DEL SUEÑO Y EL PRONÓSTICO DEL MELANOMA. ESTUDIO LONGITUDINAL Y MULTICÉNTRICO EN 443 PACIENTES CON MELANOMA CUTÁNEO MALIGNO.
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PI16/01772 . INSTITUTO DE SALUD CARLOS III . 2017
P4COPD: Prediction, Prevention, Personalized and Precision management of COPD in young adults.
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PMP21/00090 . INSTITUTO DE SALUD CARLOS III . 2022
Contratos Río Hortega 2023. GRACE JACQUELINE OSCULLO YÉPEZ
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
CM23/00015 . INSTITUTO DE SALUD CARLOS III . 2024
Registro nacional de antibóticos inhalados en patología crónica de la vía área.
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
REPAIR . 2023